Detailed Notes on M3541
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis